Tech Company Financing Transactions
GenEdit Funding Round
GenEdit secured a $24 million Series A venture capital round on 1/23/2024. Investors included ACVC Partners, DAYLI Partners and Dong-A ST.
Transaction Overview
Company Name
Announced On
1/23/2024
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series A
Investors
Eli Lilly and Company (Andrew Adams)
Proceeds Purpose
The funding will support continued development of the NanoGalaxy platform and a pipeline of preclinical therapeutic candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. 3rd Foor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kunwoo Lee
Chief Financial Officer
Aaron Mishel
Chief Scientific Officer
Romuald Corbau
Chief Technical Officer
Timothy Fong
Vice President
Yvonne Angell
Vice President
Derek Sloan
VP - Bus. Development
Jennifer Cygan
VP - Operations
Hyo Park
Browse more venture capital transactions:
Prev: 1/23/2024: Elephas Biosciences venture capital transaction
Next: 1/23/2024: Daytrip venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs